Blog

Digitally Transforming Pharmacovigilance Processes Remains a Key Life Sciences Priority

On June 9, 2020 ArisGlobal held a webinar titled “Pharmacovigilance and Digital Transformation: Stepping into the Technology-Driven Future.” During the webinar, over half (58%) of the attendees indicated that they are no longer relying on Microsoft Excel workbooks to manage case activities such as allocation, workflow management and query tracking. ArisGlobal has noted a continuous trend away from manual processesOn October 15th of 2019, for example, during ArisGlobal’s, Automation in Pharmacovigilance: From Hype to Reality webinar, nearly half (43%) of all respondents considered automation of pharmacovigilance (PV) processes to be a top priority for their organizations. 

The webinar, presented by Aman WasanSenior Vice President, Global Pharmacovigilance for ArisGlobal, focused on best practices for the transformation of case tracking from manual to automated.  

During the webinar, Aman focused on three subjects. The first being industry challenges and opportunities to digitally transform pharmacovigilance. The second subject discussed was strategies to adopt new digital pharmacovigilance initiatives successfully. And finally, the last item was tips and tricks for motivating pharmacovigilance staff to embrace change. 

 

The increased focused on adopting automation is of little surprise. As the volume of global post-marketing adverse event (AE) reports continues to rise at rate of 15% per year, it has become difficult for pharmacovigilance teams to handle an increased workload with fixed resources and tight budgets. Compounding the growing number of AE reports, safety case management has historically involved a significant amount of manual, repetitive processing work. This requires PV teams to focus more resources on operational challenges, rather than value-added safety science activities like signal detection and benefit-risk management.  

Automation has become a widely discussed topic in the industry, with many organizations actively pursuing methods of streamlining case processing through automation technologies. In fact, a recent survey conducted by McKinsey & Co, a global consultancy, found that automation capability was rated by large biopharmas as the most critical buying factor when choosing safety software.  

ArisGlobal has over 30 years of experience in the Life Sciences industry, where they have been an innovative leader in Pharmacovigilance and Drug Safety software. This experience helps us to understand these and other challenges companies face when they realize they need to automate their pharmacovigilance efforts. 

LifeSphere MultiVigilance 10 by ArisGlobal is the only automated, end-to-end safety system built with the industry, for the industry, and developed in partnership with the world’s best life sciences companies. It helps hundreds of pharmacovigilance teams worldwide save time and effort; it ensures future-proof compliance; and keeps global teams aligned. 

To learn more about LSMV10, watch our Managing and Mastering Pharmacovigilance webinar, here. 

In the next blog from this series, we will discuss how technology investments impact the quality of existing safety data. You can also view this on-demand webinar here. 

(This is Blog #1 in a two-part series covering the Pharmacovigilance and Digital Transformation: Stepping into the Technology-Driven Future webinar.) 

OTHER ARTICLES THAT MIGHT INTEREST YOU